Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Agilent Technologies's operating assets for the quarter that ended in Apr. 2026 was €9,626 Mil. Agilent Technologies's operating liabilities for the quarter that ended in Apr. 2026 was €2,213 Mil. Agilent Technologies's Total Assets for the quarter that ended in Jan. 2026 was €10,904 Mil. Therefore, Agilent Technologies's scaled net operating assets (SNOA) for the quarter that ended in Apr. 2026 was 0.68.
Agilent Technologies Scaled Net Operating Assets Related Terms
Agilent Technologies Scaled Net Operating Assets Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies Scaled Net Operating Assets Chart
FRA:AG8 vs NTRA, WAT, IDXX: Scaled Net Operating Assets Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Scaled Net Operating Assets vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Scaled Net Operating Assets falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Scaled Net Operating Assets of 0.68 mean?
Agilent Technologies (FRA:AG8) has a Scaled Net Operating Assets of 0.68 as of Apr. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Agilent Technologies and its competitors.
Is Agilent Technologies' Scaled Net Operating Assets too high?
Agilent Technologies' current Scaled Net Operating Assets is 0.68. Overall, Agilent Technologies has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Scaled Net Operating Assets compare to NTRA and WAT?
Agilent Technologies' Scaled Net Operating Assets of 0.68 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Medical Diagnostics & Research company?
A good Scaled Net Operating Assets depends on the Medical Diagnostics & Research industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Scaled Net Operating Assets is 0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Modestly Undervalued. The stock's GF Value™ is €127.15, compared to a current price of €114.00 — trading 10.3% below its estimated fair value. The current Scaled Net Operating Assets is 0.68. Agilent Technologies' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current Scaled Net Operating Assets is 0.68 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €114.00 is trading 10.3% below its estimated GF Value™ of €127.15.
GuruFocus considers Agilent Technologies to be Modestly Undervalued.
Key valuation signals for FRA:AG8:
Scaled Net Operating Assets: 0.68
GF Value™: €127.15 vs. price of €114.00 (10.3% below fair value)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
94GF Score
Get the complete analysis for FRA:AG8
Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
